The FDA has approved Agios' first-in-class Pyrukynd. This oral medication is the first FDA-approved medicine for the rare and debilitating blood disorder, hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
Before the approval, the only options for treatment were red blood cell transfusions or spleen removal surgery, Agios says, which both come with risks and burdens.
Click here to read the entire article.